Evidence map›Paper›PMID 28270871›Full record

ArticleGastroenterology research2017

Antiviral Therapy in Chronic Hepatitis B With Mild Acute Exacerbation.

Su Lin, Qiaoxia Ye, Mingfang Wang, Yinlian Wu, Zhiyuan Weng, Yueyong Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastroenterology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Su LinLiver Research Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
Qiaoxia YeLiver Research Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China; Clinical Liver Center of the 180th Hospital of People's Liberation Army, Quanzhou 362100, China.
Mingfang WangLiver Research Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
Yinlian WuLiver Research Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
Zhiyuan WengCardiology Department, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
Yueyong ZhuLiver Research Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study was to assess the efficacy and safety of peginterferon α-2a (pegIFN) and nucleos(t)ide analogues (NA) treatments in patients with hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B (CHB) with mild acute exacerbation (AE).

methodsTreatment-naive HBeAg-positive CHB patients with AE who received pegIFN or NA (entecavir (ETV) or telbivudine (LDT)) therapies were retrospectively selected. The HBeAg seroconversion rate, hepatitis B surface antigen (HBsAg) loss rate and the cost-effectiveness of different treatments were compared.

resultsA total of 63 patients with pegIFN therapy and 78 with NA (38 with ETV and 40 with LDT) therapy were included. The HBsAg loss rate was significantly higher in the pegIFN group when compared with the NA group (on week 96: 9/63 (14.29%) vs. 1/78 (1.28%), P = 0.005). No significant difference in hepatitis B virus (HBV) DNA negativity or the HBeAg/HBsAg seroconversion rate was found between ETV and LDT group. One year of pegIFN therapy resulted in 18.56 quality-adjusted life years (QALYs) per patient, and the incremental cost per additional QALY gained was $3,709.

conclusionsPegIFN therapy is safe in HBeAg-positive CHB patients with mild AE, as it results in a higher HBsAg loss rate and longer QALYs than NA therapy.

Indexed as

Acute exacerbationChronic hepatitis BEntecavirPeginterferon α-2aTelbivudine

Identifiers

PMID28270871
PMCPMC5330687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.